She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...